☆ 4.4 Letter

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

HAEMATOLOGICA (2021)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 106, Issue 8, Pages 2242-2245

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2020.261354

Keywords

-

Categories

Hematology

Funding

  1. National Institutes of Health [U10 CA98543, U10 CA180886, U10 CA98413, U10 CA180899, U24 CA114766, U24-CA196173]
  2. American Lebanese Syrian Associated Charities
  3. Innovation Grant of Alex's Lemonade Stand Foundation
  4. Frank A. Campini Foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.